NASDAQ:DTIL Precision BioSciences (DTIL) Stock Price, News & Analysis $9.15 -0.35 (-3.68%) Closing price 04:00 PM EasternExtended Trading$9.12 -0.04 (-0.38%) As of 04:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Precision BioSciences Stock (NASDAQ:DTIL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Precision BioSciences alerts:Sign Up Key Stats Today's Range$8.93▼$9.5950-Day Range$5.77▼$10.6052-Week Range$3.53▼$11.29Volume251,718 shsAverage Volume324,261 shsMarket Capitalization$255.65 millionP/E RatioN/ADividend YieldN/APrice Target$32.25Consensus RatingModerate Buy Company Overview Precision BioSciences, Inc. is a biotechnology company developing gene-editing medicines using its proprietary ARCUS platform. ARCUS is based on engineered DNA-cutting enzymes designed to make targeted changes to genetic material, with the potential to remove, insert or correct DNA sequences in human cells. The company’s research and development activities have focused primarily on in vivo gene editing, in which therapeutic editing components are delivered directly into the body. Its development programs have included potential treatments for conditions such as chronic hepatitis B infection, Duchenne muscular dystrophy and certain rare genetic disorders. Precision BioSciences has also pursued collaborations and licensing arrangements to apply its gene-editing technology to additional therapeutic areas. Founded in 2006 and headquartered in Durham, North Carolina, Precision BioSciences became a publicly traded company in 2019. Its products remain in development, and the company’s operations are centered on biotechnology research, preclinical development and clinical-stage evaluation of gene-editing candidates for patients in the United States and international markets.AI Generated. May Contain Errors. Read More Precision BioSciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks67th Percentile Overall ScoreDTIL MarketRank™: 3.34401569653 of 5 starsPrecision BioSciences scored higher than 67% of companies evaluated by MarketBeat, and ranked 275th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingModerate Buy Consensus RatingPrecision BioSciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on no strong buy ratings, 4 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialPrecision BioSciences has a consensus price target of $32.25, representing about 252.5% upside from its current price of $9.15.Amount of Analyst CoveragePrecision BioSciences has only been the subject of 1 research reports in the past 90 days.Read more about Precision BioSciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Precision BioSciences are expected to grow in the coming year, from ($2.60) to ($1.92) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Precision BioSciences is -7.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Precision BioSciences is -7.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPrecision BioSciences has a P/B Ratio of 4.95. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.71% of the float of Precision BioSciences has been sold short.Short Interest Ratio / Days to CoverPrecision BioSciences has a short interest ratio ("days to cover") of 10.52, which indicates bearish sentiment.Change versus previous monthShort interest in Precision BioSciences has recently decreased by 11.03%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPrecision BioSciences does not currently pay a dividend.Dividend GrowthPrecision BioSciences does not have a long track record of dividend growth. News and Social Media2.6 / 5News Sentiment0.17 News SentimentPrecision BioSciences has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 18 news articles for Precision BioSciences this week, compared to 2 articles on an average week.MarketBeat Follows4 people have added Precision BioSciences to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership4.1 / 5Insider TradingAcquiring Shares Cluster Insider Buying3 insiders have purchased shares of Precision BioSciences in the last three months. Multiple insiders buying is a strong bullish signal.Net Insider BuyingOver the last three months, insiders have purchased a net $29,501.00 in company stock, which represents 0.0115% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Precision BioSciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $29,501.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders2.70% of the stock of Precision BioSciences is held by insiders.Percentage Held by Institutions37.99% of the stock of Precision BioSciences is held by institutions.Read more about Precision BioSciences' insider trading history. Receive DTIL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Precision BioSciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DTIL Stock News HeadlinesPrecision BioSciences, Inc. (DTIL) Discusses Phase 1 ELIMINATE-B Data for PBGENE-HBV in Chronic Hepatitis B TranscriptNovember 9 at 6:00 PM | seekingalpha.comHC Wainwright Has Bullish Estimate for DTIL FY2026 EarningsNovember 9 at 2:01 AM | americanbankingnews.comI'm handing you this stock todayElon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout.November 11 at 1:00 AM | Behind the Markets (Ad)Precision BioSciences (NASDAQ:DTIL) Upgraded to Hold at Wall Street ZenNovember 7, 2026 | americanbankingnews.comPrecision BioSciences prices 10.24M shares at $7.75 in underwritten offeringNovember 5, 2026 | finance.yahoo.comH.C. Wainwright Sticks to Their Buy Rating for Precision BioSciences (DTIL)November 4, 2026 | theglobeandmail.comPrecision BioSciences, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2026November 3, 2026 | marketscreener.comMPrecision BioSciences Reports Third Quarter 2026 Financial Results and Provides Business UpdateNovember 3, 2026 | businesswire.comSee More Headlines DTIL Stock Analysis - Frequently Asked Questions How have DTIL shares performed this year? Precision BioSciences' stock was trading at $4.16 at the beginning of the year. Since then, DTIL shares have increased by 120.0% and is now trading at $9.15. How were Precision BioSciences' earnings last quarter? Precision BioSciences, Inc. (NASDAQ:DTIL) released its earnings results on Tuesday, November, 3rd. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.85) by $0.57. Precision BioSciences had a negative net margin of 96.73% and a negative trailing twelve-month return on equity of 56.69%. When did Precision BioSciences' stock split? Precision BioSciences's stock reverse split on Wednesday, February 14th 2024.The 1-30 reverse split was announced on Wednesday, February 14th 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, February 14th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did Precision BioSciences IPO? Precision BioSciences (DTIL) raised $126 million in an initial public offering on Thursday, March 28th 2019. The company issued 7,900,000 shares at $15.00-$17.00 per share. J.P. Morgan, Goldman Sachs, Jefferies and Barclays acted as the underwriters for the IPO. Who are Precision BioSciences' major shareholders? Precision BioSciences' top institutional shareholders include Russell Investments Group Ltd. (0.30%) and Aberdeen Group plc (0.10%). Insiders that own company stock include Michael Amoroso, John Alexander Kelly, J Jefferson Smith, Geno J Germano, Melinda Brown, Stanley Frankel, Dario Scimeca and Alan List. View institutional ownership trends. How do I buy shares of Precision BioSciences? Shares of DTIL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Precision BioSciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Precision BioSciences investors own include Editas Medicine (EDIT), NVIDIA (NVDA), Kaleido Biosciences (KLDO), Tesla (TSLA), Micron Technology (MU), Advanced Micro Devices (AMD) and CRISPR Therapeutics (CRSP). Company Calendar Last Earnings11/03/2026Today11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 3 weeks, DTIL's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:DTIL CIK1357874 Webwww.precisionbiosciences.com Phone(919) 314-5512FaxN/AEmployees67Year Founded2006Price Target and Rating Average Price Target for Precision BioSciences$32.25 High Price Target$60.00 Low Price Target$19.00 Potential Upside/Downside+252.5%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($1.24) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$45.72 million Net Margins-96.73% Pretax Margin-87.54% Return on Equity-56.69% Return on Assets-27.63% Debt Debt-to-Equity Ratio0.43 Current Ratio10.47 Quick Ratio10.47 Sales & Book Value Annual Sales$34.26 million Price / Sales7.46 Cash FlowN/A Price / Cash FlowN/A Book Value$1.85 per share Price / Book4.95Miscellaneous Outstanding Shares27,940,000Free Float27,182,000Market Cap$255.65 million OptionableOptionable Beta1.34 Social Links The 7 Best High-Yield Dividend Stocks for 2027Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.Get This Free Report This page (NASDAQ:DTIL) was last updated on 11/11/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | SponsoredDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...TradeWins | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Precision BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Precision BioSciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
